Home » Posts tagged with » Pfizer
Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech

Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech

Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the use of the BNT162b2 Covid-19 vaccine from US pharma giant Pfizer and German biotech company BioNTech. The Swiss pharma regulator said that as per the data it has assessed, the level of protection afforded seven days following the second dose of the mRNA vaccine is […]

Pfizer and BioNTech secure FDA EUA for BNT162b2 Covid-19 vaccine

BNT162b2 FDA EUA : Pfizer and BioNTech have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for BNT162b2, their Covid-19 mRNA vaccine. BNT162b2 has been authorized by the FDA for its use in the prevention of Covid-19 in individuals aged 16 years or more. Pfizer and BioNTech will look […]

Continue reading …
Pfizer, BioNTech get Canadian approval for BNT162b2 Covid-19 vaccine

US pharma giant Pfizer and German biotech company BioNTech have bagged Health Canada approval for their BNT162b2 Covid-19 vaccine. The BNT162b2 vaccine has been authorized to be used in Canada under the regulator’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada has now joined the UK […]

Continue reading …
PostEra, Pfizer partner to advance machine learning for drug discovery

PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of small molecule drugs by using a platform technology based on generative chemistry. The company’s machine learning technology can fast track the drug discovery process by designing novel molecular structures that […]

Continue reading …
UK authorizes Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine

The UK has given a temporary authorization for emergency use for the BNT162b2 Covid-19 vaccine candidate developed by Pfizer and BioNTech. The emergency use authorization (EUA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for the mRNA vaccine candidate follows the release of positive results of a global phase 3 trial. Pfizer and […]

Continue reading …
Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer. OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Its combination with the Pfizer breast cancer drug will be assessed in the […]

Continue reading …
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

Continue reading …
Pfizer’s tofacitinib succeeds in phase 3 ankylosing spondylitis trial

Pfizer said that a phase 3 clinical trial of XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS) has met its primary endpoint. The late-stage study’s primary endpoint is assessment in SpondyloArthritis International Society (ASAS) 20 response, compared to placebo at week 16. This was after the percentage of patients achieving an ASAS20 response was […]

Continue reading …
FTC gives conditional approval to Mylan’s acquisition of Upjohn from Pfizer

The US Federal Trade Commission (FTC) has granted conditional approval for Dutch pharma company Mylan’s acquisition of Upjohn, the off-patent branded and generic established medicines business of Pfizer. The deal was announced in July 2019 with an objective to create a new global pharma company through the merger of Mylan and Upjohn, which will be […]

Continue reading …
IBRANCE fails to meet primary endpoint in early breast cancer trial

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage trial is being held by the US pharma giant with the German Breast Group (GBG) sponsoring it. The primary endpoint of the PENELOPE-B clinical trial is improved invasive disease-free survival […]

Continue reading …
Page 1 of 41234